← Oncology Approval Tracker

FDA DECISION ·

Retacrit

epoetin alfa-epbx · Hospira

FDA approvalNew formulationChemotherapy-associated anemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Approved new multidose vial presentations of the epoetin alfa biosimilar; oncology use covered anemia caused by concomitant myelosuppressive chemotherapy in patients with nonmyeloid malignancies meeting the label’s criteria.

LAMPGEN ANALYSIS

Why it matters

Added vial choices for an existing erythropoiesis-stimulating agent with labeled chemotherapy-associated anemia use.

What research teams should watch

Distinguish multidose from single-dose inventory and retain the label’s transfusion, hemoglobin and treatment-intent checks.

PRIMARY RECORDS

Sources